Neuroimaging/External Links: Difference between revisions
Jump to navigation
Jump to search
imported>Daniel Mietchen (+one) |
imported>Daniel Mietchen (+tools) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
==Overviews== | |||
*[http://www.scholarpedia.org/article/Category:Neuroimaging Scholarpedia articles in the category Neuroimaging] | *[http://www.scholarpedia.org/article/Category:Neuroimaging Scholarpedia articles in the category Neuroimaging] | ||
*[http://www2.imm.dtu.dk/~fn/bib/Nielsen2001BibSegmentation/Nielsen2001BibSegmentation.html Bibliography of Segmentation in Neuroimaging] | *[http://www2.imm.dtu.dk/~fn/bib/Nielsen2001BibSegmentation/Nielsen2001BibSegmentation.html Bibliography of Segmentation in Neuroimaging] | ||
==Neuroimaging tools== | |||
*[http://www.nitrc.org/ The Neuroimaging Informatics Tools and Resources Clearinghouse] | |||
==Neuroimaging databases== | ==Neuroimaging databases== | ||
*[http://www.loni.ucla.edu/ADNI/ Alzheimer's Disease Neuroimaging Initiative (ADNI)] | |||
:"The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial [[magnetic resonance imaging]] (MRI), [[positron emission tomography]] (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of [[mild cognitive impairment]] (MCI) and early [[Alzheimer's disease]] (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of [[clinical trial]]s. The Principle Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research -- approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years" | |||
*[http://www.ixi.org.uk/ IXI database at King's College London] - with brain MRI data obtained from 550 normal subjects between the age of 20 and 80 years using standardized protocols | *[http://www.ixi.org.uk/ IXI database at King's College London] - with brain MRI data obtained from 550 normal subjects between the age of 20 and 80 years using standardized protocols | ||
*[http://www.brain-child.org/ NIH MRI study of normal brain development] - described by [[CZ:Ref:Brain Development Cooperative Group 2006 The NIH MRI study of normal brain development|The Brain Development Cooperative Group and Alan Evans, 2006]] | |||
Latest revision as of 08:59, 11 November 2009
- Please sort and annotate in a user-friendly manner and consider archiving the URLs behind the links you provide. See also related web sources.
Overviews
Neuroimaging tools
Neuroimaging databases
- "The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials. The Principle Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research -- approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years"
- IXI database at King's College London - with brain MRI data obtained from 550 normal subjects between the age of 20 and 80 years using standardized protocols
- NIH MRI study of normal brain development - described by The Brain Development Cooperative Group and Alan Evans, 2006